Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

NCT03617731 is registered in ClinicalTrials.gov with University of Heidelberg Medical Center as lead sponsor.

NCT NCT03617731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03617731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
University of Heidelberg Medical Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 18, 2018
Completion date
June 30, 2028
Enrollment
662 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma